Analysis and study on the efficacy of Apelvis-Piqray in the treatment of breast cancer

Alpelisib (Alpelisib)-Piqray is an important development in the treatment of breast cancer in recent years. As an oral selective PI3Kα inhibitor, it specifically targets signaling pathway abnormalities caused by PIK3CA mutations, providing a new targeted treatment option for patients with hormone receptor-positive (ER+) and HER2-negative breast cancer. According to existing research and treatment guidelines, apelvis is often used in combination with endocrine drugs such as letrozole or fulvestrant, targeting patients who have become resistant to endocrine therapy, especially in PIK3CA mutation-positive advanced or metastatic breast cancer, which has shown significant clinical benefits.

From a mechanism perspective,The PI3K pathway plays a key role in cell proliferation, metabolism, and survival, and PIK3CA is a key gene in this pathway. Its mutation will cause the pathway to remain active, thereby promoting tumor growth. Studies have shown that approximately 40% of ER+/HER2- breast cancer patients have PIK3CA mutations, making apelvis a clear target. When combined with endocrine therapy, the drug can reverse some of the resistance mechanisms caused by mutations, improve sensitivity to hormone therapy, and extend progression-free survival in some patients.

In early dose-finding trials, the maximum tolerated dose (MTD) of apelvis combined with letrozole was determined to be 300 mg/day. Beyond this dose, more obvious dose-limiting toxic reactions will occur, among which hyperglycemia is the most common. In addition, nausea, fatigue, diarrhea and rash were also observed in many patients receiving treatment, which suggests that patients need to undergo strict blood glucose monitoring and corresponding symptomatic treatment during clinical application. Especially for patients who are at risk for insulin resistance or diabetes, the risks and benefits of apelvis treatment need to be carefully weighed.

In terms of efficacy, multiple studies have shown that the drug exhibits more significant clinical benefits in patients with PIK3CA mutation-positive patients. For example, in a clinical study, 35% of patients who received apelvis combined with letrozole effectively controlled their disease for more than 6 months, while the clinical benefit rate for PIK3CA mutation-positive people was close to 44%. Although this ratio indicates that mutation status is related to efficacy, interestingly, some patients with PIK3CA wild-type tumors also showed therapeutic response, suggesting that the anti-tumor activity of apelvis may not be entirely dependent on this mutation status.

After in-depth study of drug response differences in different genetic backgrounds, it was found that some associatedTumor cells with FGFR1 or FGFR2 amplification, KRAS or TP53 mutations have significantly reduced sensitivity to apelvis, indicating that these molecular characteristics may be related to innate or acquired resistance. In particular, FGFR1 overexpression has been confirmed to weaken the effect of apelvis in ER+/PIK3CA mutant cells, which raises new topics on how to optimize combination treatment strategies and develop composite target programs in the future.

From a safety perspective, the combination of Apelvis and Letrozole has a controllable toxicity spectrum, and most of its side effects are reversible. As long as through standard medication management and monitoring, most patients can tolerate the treatment and obtain benefits. In clinical practice, if patients can achieve long-term stable medication, for example, if they last for more than 12 months, PIK3CA mutations will be detected in most tumors. This phenomenon strengthens the guiding value of molecular subtyping in treatment selection.

Currently, multiple Phase II and Phase III clinical trials of Apelvis are being conducted around the world, with particular focus on its combined effect with different types of endocrine drugs, long-term safety evaluation, and precise treatment effects on patients with multiple mutated subtypes of breast cancer. In addition to letrozole, apelvis is also being evaluated in combination with fulvestrant, tamoxifen and other drugs in order to cover a wider patient population.

Reference materials:https://www.piqray.com/